Alcon (ALC) Stock Price, News & Analysis

Company Overview

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Key Stats

• Today's Range: $84.06 to $85.33
• 50-Day Range: $83.88 to $97.20
• 52-Week Range: $74.30 to $101.10
• Volume: 917,602 shs
• Average Volume: 849,126 shs
• Market Capitalization: $41.81 billion
• P/E Ratio: 36.22
• Dividend Yield: 0.31%
• Price Target: $102.72
• Consensus Rating: Moderate Buy

Alcon Stock Analysis - MarketRank™

Alcon scored higher than 69% of companies evaluated by MarketBeat, and ranked 328th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alcon has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alcon has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.23%

Earnings Growth

Earnings for Alcon are expected to grow by 10.23% in the coming year, from $3.03 to $3.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alcon is 36.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.38.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alcon is 36.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.67.

Price to Earnings Growth Ratio

Alcon has a PEG Ratio of 2.20. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Alcon has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.57% of the float of Alcon has been sold short.

Short Interest Ratio / Days to Cover

Alcon has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alcon has recently decreased by 11.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Alcon has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Alcon does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Alcon is 11.11%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Alcon will have a dividend payout ratio of 7.78% next year. This indicates that Alcon will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.57% of the float of Alcon has been sold short.

Short Interest Ratio / Days to Cover

Alcon has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alcon has recently decreased by 11.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.01

News Sentiment

Alcon has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Alcon this week, compared to 4 articles on an average week.

Search Interest

14 people have searched for ALC on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

1 people have added Alcon to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alcon insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.52% of the stock of Alcon is held by insiders.

Percentage Held by Institutions

53.86% of the stock of Alcon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALC Stock Analysis - Frequently Asked Questions

How have ALC shares performed this year?

Alcon's stock was trading at $78.12 on January 1st, 2024. Since then, ALC shares have increased by 8.5% and is now trading at $84.76.
View the best growth stocks for 2024 here.

How were Alcon's earnings last quarter?

Alcon Inc. (NYSE:ALC) issued its quarterly earnings data on Tuesday, November, 12th. The healthcare company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.09. The healthcare company had revenue of $2.45 billion for the quarter, compared to analyst estimates of $2.45 billion. Alcon had a trailing twelve-month return on equity of 7.17% and a net margin of 11.89%.

Does Alcon have any subsidiaries?

Alcon subsidiaries include Alcon (China) Ophthalmic Product Co. Ltd., Alcon Finance Corporation, Alcon Japan Ltd., Alcon Laboratories Inc., Alcon Pharmaceuticals Ltd., Alcon Research LLC, and Alcon Vision LLC.

Who are Alcon's major shareholders?

Alcon's top institutional investors include FMR LLC (2.91%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.44%), Zurcher Kantonalbank Zurich Cantonalbank (1.75%) and Vontobel Holding Ltd. (1.49%).

How do I buy shares of Alcon?

Shares of ALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Alcon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alcon investors own include Coca-Cola (KO), AT&T (T), Walt Disney (DIS), PepsiCo (PEP), Verizon Communications (VZ), Cisco Systems (CSCO) and Johnson & Johnson (JNJ).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Ophthalmic goods
• Sub-Industry: Health Care Facilities
• Current Symbol: NYSE:ALC
• CUSIP: 04544X30
• CIK: 929994
• Web: www.alcon.com
• Phone: 418172930450
• Fax: 41-58-911-3222
• Employees: 25,000
• Year Founded: 1945

Price Target and Rating

• Average Stock Price Target: $102.72
• High Stock Price Target: $110.00
• Low Stock Price Target: $85.00
• Potential Upside/Downside: +21.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.34
• Trailing P/E Ratio: 36.22
• Forward P/E Ratio: 27.97
• P/E Growth: 2.2
• Net Income: $974 million
• Net Margins: 11.89%
• Pretax Margin: 11.01%
• Return on Equity: 7.17%
• Return on Assets: 5.03%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 2.57
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $9.76 billion
• Price / Sales: 4.28
• Cash Flow: $5.13 per share
• Price / Cash Flow: 16.51
• Book Value: $41.81 per share
• Price / Book: 2.03

Miscellaneous

• Outstanding Shares: 493,244,000
• Free Float: 485,747,000
• Market Cap: $41.81 billion
• Optionable: Optionable
• Beta: 0.98